12:00 AM
Dec 23, 2013
 |  BC Week In Review  |  Clinical News  |  Regulatory

Lixiana edoxaban regulatory update

Daiichi submitted an sNDA to Japan's Ministry of Health, Labor and Welfare (MHLW) for Lixiana edoxaban to treat non-valvular atrial fibrillation (AF) and symptomatic venous thromboembolism (VTE). The oral factor Xa inhibitor is approved in Japan to prevent VTE after major orthopedic surgery. By next quarter, Daiichi plans to...

Read the full 231 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >